Sample/probe . | Normal . | Expanded or ectopic . | Diminished . | |
---|---|---|---|---|
C-TSK siRNA (C-TSK-si) 0.5 pmol | ||||
Sox9 | 26 | 0 | 0 | |
Xslug | 28 | 0 | 0 | |
Zic5 | 25 | 0 | 0 | |
Hairy2A | 39 | 0 | 0 | |
Msx-1 | 45 | 0 | 1 | |
XK81 | 21 | 1 | 2 | |
Xrx1 | 9 | 0 | 0 | |
X-TSK siRNA (X-TSK-si) 0.5 pmol | ||||
Sox9 | 15 | 0 | 51 (77.3%) | |
Xslug | 17 | 0 | 39 (69.6%) | |
Zic5 | 3 | 0 | 17 (85.0%) | |
Hairy2A | 8 | 0 | 28 (77.8%) | |
Msx-1 | 16 | 0 | 37 (69.8%) | |
Sox2 | 24 | 0 | 0 | |
XK81 | 15 | 37 (71.2%) | 0 | |
Xbmp4 | 11 | 1 | 0 | |
Xrx1 | 16 | 0 | 1 | |
Control morpholino (CMO) 5 ng | ||||
Sox9 | 14 | 0 | 0 | |
X-TSK morpholino (X-TSK-MO) 5 ng | ||||
Sox9 | 11 | 0 | 23 (67.6%) | |
Xslug | 16 | 0 | 39 (70.9%) |
Sample/probe . | Normal . | Expanded or ectopic . | Diminished . | |
---|---|---|---|---|
C-TSK siRNA (C-TSK-si) 0.5 pmol | ||||
Sox9 | 26 | 0 | 0 | |
Xslug | 28 | 0 | 0 | |
Zic5 | 25 | 0 | 0 | |
Hairy2A | 39 | 0 | 0 | |
Msx-1 | 45 | 0 | 1 | |
XK81 | 21 | 1 | 2 | |
Xrx1 | 9 | 0 | 0 | |
X-TSK siRNA (X-TSK-si) 0.5 pmol | ||||
Sox9 | 15 | 0 | 51 (77.3%) | |
Xslug | 17 | 0 | 39 (69.6%) | |
Zic5 | 3 | 0 | 17 (85.0%) | |
Hairy2A | 8 | 0 | 28 (77.8%) | |
Msx-1 | 16 | 0 | 37 (69.8%) | |
Sox2 | 24 | 0 | 0 | |
XK81 | 15 | 37 (71.2%) | 0 | |
Xbmp4 | 11 | 1 | 0 | |
Xrx1 | 16 | 0 | 1 | |
Control morpholino (CMO) 5 ng | ||||
Sox9 | 14 | 0 | 0 | |
X-TSK morpholino (X-TSK-MO) 5 ng | ||||
Sox9 | 11 | 0 | 23 (67.6%) | |
Xslug | 16 | 0 | 39 (70.9%) |
C-TSK siRNA (C-TSK-si), X-TSK siRNA(X-TSK-si) was injected into unilateral blastomeres at the four-cell stage. Embryos showing identical effects on the injected side were counted at stage 15.